{
  "first_published_at": "2009-12-01", 
  "original_url": "http://www.mhra.gov.uk/Safetyinformation/DrugSafetyUpdate/CON087719", 
  "title": "Rituximab: progressive multifocal leukoencephalopathy in a patient without prior treatment for rheumatoid arthritis", 
  "tags": "{\"parsed_therapeutic\": [\"cancer\", \"rheumatology\"], \"Audience:\": [\"Primary care\", \"Secondary care\"], \"Therapeutic area:\": [\"Cancer\", \"Rheumatology\"]}", 
  "_document_number": 227, 
  "label": null, 
  "icon": "http://www.mhra.gov.uk/home/images/MHRALook/img/dsu/adverse_icon.png", 
  "therapeutic_area": [
    "cancer", 
    "rheumatology"
  ], 
  "raw_html": "<div id=\"dsuArticleContent\">\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\t<h1><a name=\"maincontent\" id=\"maincontent\"></a>Rituximab: progressive multifocal leukoencephalopathy in a patient without prior treatment for rheumatoid arthritis</h1>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<span class=\"ref\">Article date: December 2009</span> \r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t<!--In September 2009, a case of progressive multifocal leukoencephalopathy (PML) with a fatal outcome was reported in a patient with rheumatoid arthritis who had not previously received treatment with methotrexate or a TNF antagonist-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element21)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element22)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!--SS_BEGIN_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t<!--<p>Rituximab (MabThera) in combination with methotrexate is indicated for the treatment of adults with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying antirheumatic drugs including one or more tumour necrosis factor (TNF) inhibitor therapies. Rituximab is also indicated for treatment of non-Hodgkin&rsquo;s lymphoma and chronic lymphocytic leukaemia in combination with chemotherapy.</p><p>In September 2009, a case of progressive multifocal leukoencephalopathy (PML) with a fatal outcome was reported in a patient with rheumatoid arthritis who had not previously received treatment with methotrexate or a TNF antagonist. This case is the third case of PML reported in a patient with rheumatoid arthritis who was receiving rituximab. Cases of PML have also been reported in patients with other autoimmune diseases treated with rituximab.</p><p>A <a href=\"http://http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON063058\" target=\"_blank\">letter has been sent to relevant healthcare professionals</a> to inform of this case and to remind that rituximab is not indicated for first-line treatment of rheumatoid arthritis.</p><p>&nbsp;</p><p><em>Article citation: Drug Safety Update Dec 2009, vol 3 issue 5: 7b.</em></p>-->\r\n\t\t\t\t\t\t\t\t<!--SS_END_ELEMENT(region1_element13)-->\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_BEGIN_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t\t<!-- call include to dynamically insert alt attributes into image tags within a wysiwyg element -->\r\n<!-- get a reference to the wysiwyg content -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n<!-- parse hyperlinked images -->\r\n<!-- parse word documents -->\r\n<!-- parse powerpoint documents -->\r\n<!-- parse excel documents -->\r\n<!-- parse pdf documents -->\r\n<!-- parse links to the site -->\r\n<!-- remove all hardlinks to cms -->\r\n<!-- replace /stellent/ with current webroot -->\r\n\t<p>Rituximab (MabThera) in combination with methotrexate is indicated for the treatment of adults with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying antirheumatic drugs including one or more tumour necrosis factor (TNF) inhibitor therapies. Rituximab is also indicated for treatment of non-Hodgkin&#8217;s lymphoma and chronic lymphocytic leukaemia in combination with chemotherapy.</p><p>In September 2009, a case of progressive multifocal leukoencephalopathy (PML) with a fatal outcome was reported in a patient with rheumatoid arthritis who had not previously received treatment with methotrexate or a TNF antagonist. This case is the third case of PML reported in a patient with rheumatoid arthritis who was receiving rituximab. Cases of PML have also been reported in patients with other autoimmune diseases treated with rituximab.</p><p>A <a href=\"http://http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON063058\" target=\"_blank\">letter has been sent to relevant healthcare professionals</a> to inform of this case and to remind that rituximab is not indicated for first-line treatment of rheumatoid arthritis.</p><p>&#160;</p><p><em>Article citation: Drug Safety Update Dec 2009, vol 3 issue 5: 7b.</em></p>\r\n\t\t\t\r\n\t\t\t\t\t\t\t\t<!-- SS_END_SNIPPET(fragment7,1)-->\r\n\t\t\t\t\t\t\t</div>\r\n\t\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t\r\n\t\t\t\t\t\t\t", 
  "date_of_article": "2009-12-01", 
  "date_last_modified": "2010-08-24", 
  "_assets": [], 
  "_item_id": 227, 
  "summary": "", 
  "body": "Article date: December 2009\n\nRituximab (MabThera) in combination with methotrexate is indicated for the treatment of adults with severe active rheumatoid arthritis who have had an inadequate response or intolerance to other disease-modifying antirheumatic drugs including one or more tumour necrosis factor (TNF) inhibitor therapies. Rituximab is also indicated for treatment of non-Hodgkin’s lymphoma and chronic lymphocytic leukaemia in combination with chemotherapy.\n\nIn September 2009, a case of progressive multifocal leukoencephalopathy (PML) with a fatal outcome was reported in a patient with rheumatoid arthritis who had not previously received treatment with methotrexate or a TNF antagonist. This case is the third case of PML reported in a patient with rheumatoid arthritis who was receiving rituximab. Cases of PML have also been reported in patients with other autoimmune diseases treated with rituximab.\n\nA [letter has been sent to relevant healthcare professionals](http://http://www.mhra.gov.uk/Safetyinformation/Safetywarningsalertsandrecalls/Safetywarningsandmessagesformedicines/Monthlylistsofinformationforhealthcareprofessionalsonthesafetyofmedicines/CON063058) to inform of this case and to remind that rituximab is not indicated for first-line treatment of rheumatoid arthritis.\n\n \n\nArticle citation: Drug Safety Update Dec 2009, vol 3 issue 5: 7b.\n"
}